LivaNova (NASDAQ:LIVN) Given Buy Rating at Needham & Company LLC

LivaNova (NASDAQ:LIVN)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a research note issued on Tuesday,Benzinga reports. They presently have a $75.00 target price on the stock. Needham & Company LLC’s price objective suggests a potential upside of 41.14% from the stock’s current price.

Several other equities analysts have also recently issued reports on LIVN. Stifel Nicolaus boosted their target price on LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Mizuho decreased their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Robert W. Baird boosted their price target on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Friday. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $69.17.

LivaNova Trading Up 2.6 %

Shares of NASDAQ:LIVN traded up $1.33 on Tuesday, reaching $53.14. 158,735 shares of the company traded hands, compared to its average volume of 618,524. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The business’s 50-day simple moving average is $51.40 and its 200 day simple moving average is $53.00. The stock has a market capitalization of $2.89 billion, a P/E ratio of 126.74 and a beta of 1.01. LivaNova has a 52 week low of $42.75 and a 52 week high of $64.47.

Institutional Trading of LivaNova

A number of hedge funds have recently made changes to their positions in LIVN. Fifth Third Bancorp increased its position in LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after buying an additional 332 shares in the last quarter. Hexagon Capital Partners LLC increased its holdings in shares of LivaNova by 117.8% during the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after acquiring an additional 370 shares in the last quarter. Lazard Asset Management LLC purchased a new position in shares of LivaNova in the 1st quarter worth about $84,000. Canada Pension Plan Investment Board bought a new position in LivaNova in the 2nd quarter worth about $88,000. Finally, Acadian Asset Management LLC purchased a new stake in LivaNova during the 1st quarter valued at about $94,000. 97.64% of the stock is owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.